Janssen Submits NDA Seeking Approval Of Investigational Single Tablet Combination Therapy Of Macitentan And Tadalafil
Portfolio Pulse from Benzinga Newsdesk
Janssen has submitted a New Drug Application (NDA) for a single tablet combination therapy of macitentan and tadalafil for the long-term treatment of pulmonary arterial hypertension in adult patients.
May 30, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Janssen, a subsidiary of Johnson & Johnson, submitted an NDA for a combination therapy for pulmonary arterial hypertension treatment.
The submission of the NDA for the combination therapy indicates progress in Janssen's product pipeline, which could potentially lead to increased revenues for Johnson & Johnson if the drug is approved. This positive development is likely to have a short-term positive impact on JNJ's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100